🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

Recruitingn/aAges 18 Years - anyAllUniversity of Florence
NCT06628921 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the third edition of the ICHD (ICHD-III). * At least 8 days of migraine per month. * Adequate compliance with study procedures. * Availability of a migraine diary for at least one month prior to enrollment. * Ongoing attack before administration. * Included in the TACHIS study (NCT06409845) Exclusion Criteria: * Subjects with contraindications to the use of eptinezumab. * Concomitant diagnosis of medical conditions and/or comorbidities that, in the investigator's opinion, could interfere with the study's assessments and outcomes. * Pregnancy and breastfeeding. * Changes in concomitant preventive therapy in the month prior to the initiation of eptinezumab.
💊

What it tests

  • Eptinezumab 100 or 300 mg ev
📍

Where

1 site
Campus Biomedico
Roma, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy